“It often leads to a cascade of events that include further complications, extended post-acute care and even death. Nadav Ben-Dov, CEO and co-founder of phenofAST. “AST methods available today have a 2-3 day turnaround, even though the patient requires treatment now,” noted Dr. This game-changing turnaround time means that the clinical team can get the results and prescribe the right antibiotic in the same shift. Using its proprietary optical technology and AI, phenofAST will be able to produce definitive AST results directly from raw urine samples in only 4 hours. PhenofAST’s first product addresses urinary tract infections (UTI), the most prevalent hospital acquired infection. This elevates the incidence of AMR, prolonging length of hospital stay, and increasing costs. Today, clinical teams must wait days for lab results and, as a result, the patient may end up receiving the wrong antibiotic.
PhenofAST is taking on the growing threat of antimicrobial resistance (AMR), fueled by the inability of clinicians to get definitive results of antimicrobial susceptibility testing (AST) when they need it. MindUP has a strong interest in this type of multidisciplinary project that can shape the future of health care. phenofAST is bringing a unique, bio-convergent AST solution that combines cutting edge technologies in engineering and microbiology. MindUP, a leading Israeli digital health incubator, is pleased to welcome phenofAST to its family of portfolio companies.
0 kommentar(er)
